Case Study
A Geographic Roll-out Plan in the Rare Disease Space
Discover how IQVIA identified high-cost analogues to help inform the market strategy for a company looking to allocate appropriate investment for their product across various regions.
Apr 26, 2024

Anyone working within Global Portfolio Strategy, Commercial Capabilities, Operations or Strategy, or as a Chief Marketing Officer in the rare disease arena will understand the challenges faced when launching treatment effectively, due to fewer, and often geographically scattered patients. Finding rare condition patients, fostering treatment accessibility, and understanding uptake potential are top of the agenda when building a market expansion strategy to ensure that both patients are helped, and optimal return on investment is achieved. 

A pharmaceutical company focused on the rare disease space approached IQVIA looking to do exactly this. Having decided to look for analogues and observe product uptake in different geographies to support their investment allocation for their company's geographic roll-out plan, they required specialist support to identify up to six ideal high-cost analogues.

Challenges

  • The challenges the company faced were two-fold: firstly, finding the information they required and secondly turning the information into usable insight to inform their decisions.
  • Finding uptake curves for rare diseases, specifically for countries outside of the major markets proved difficult.
  • Identifying the appropriate analogues that met their target parameters.
  • Obtaining historical data and making assumptions to estimate patient equivalents in order to compare the patient pool.
  • Understanding uptake speed (initial velocity and time to peak) by country.

Overcoming these challenges required finding a way to estimate uptake for rare diseases. This needed to include speed of uptake, time to peak, patient adoption, patient days, reimbursement, label expansions, clinical factors, and more. The ability to benchmark their project against other historical rare disease analogues was also a key requirement.

Fill in your details on your left, to uncover the steps and key takeaways to success in this case study!

Related solutions

Contact Us